Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with "Treat-and-Extend" Regimen-Its Usefulness and Problems.
Shinichiro ChujoMasahiko SugimotoTaku SasakiYoshitsugu MatsuiKumiko KatoAtsushi IchioRyohei MiyataHisashi MatsubaraMineo KondoPublished in: Journal of clinical medicine (2020)
No significant differences were detected in the improvements of BCVA or CRT and injection numbers between the IVR and IVA groups treated with the TAE regimen. These results indicate that the results of the treatment with both agents with the TAE regimen were equally effective, but only 20.8% of patients completed 24 months of continuous treatment with the TAE regimen. Synopsis: There are no significant differences regarding effectiveness between the IVR and IVA groups treated with the TAE regimen for DME eyes.
Keyphrases
- age related macular degeneration
- newly diagnosed
- diabetic retinopathy
- end stage renal disease
- randomized controlled trial
- mental health
- systematic review
- ejection fraction
- chronic kidney disease
- optical coherence tomography
- peritoneal dialysis
- prognostic factors
- type diabetes
- combination therapy
- skeletal muscle
- replacement therapy